NCT06592768View on ClinicalTrials.gov

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions
Allergic Asthma
Interventions
DRUG

Briquilimab

Subcutaneous Administration

OTHER

Placebo Comparator

Subcutaneous Administration

Trial Locations (6)

T2N 1N4

University of Calgary, Calgary

T6G 2R3

University of Alberta, Edmonton

V6T 1Z4

University of British Columbia, Vancouver

L8N 3Z5

McMaster University, Hamilton

G1V 0A6

University of Laval, Québec

S7N 5A2

University of Saskatchewan, Saskatoon

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY